Leerink Positive on BioMarin (BMRN) Following BMN 270 Phase 1/2 Data; Affirms at 'Outperform'
Tweet Send to a Friend
Leerink affirms BioMarin (Nasdaq: BMRN) with an Outperform rating and $107 price target after the company announced positive interim results ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
